Astragalin Alleviates Neuropathic Pain by Suppressing P2X4-Mediated Signaling in the Dorsal Root Ganglia of Rats

Neurologic damage often leads to neuropathic pain, for which there are no effective treatments owing to its complex pathogenesis. The purinergic receptor P2X4 is closely associated with neuropathic pain. Astragalin (AST), a compound that is used in traditional Chinese medicine, has protective effect...

Full description

Published in: Frontiers in neuroscience Vol. 14; p. 570831
Main Authors: Wang, Mengke, Cai, Xia, Wang, Yueying, Li, Shizhen, Wang, Na, Sun, Rui, Xing, Jingming, Liang, Shangdong, Liu, Shuangmei
Format: Journal Article
Language: English
Published: Switzerland Frontiers Research Foundation 2020
Frontiers Media S.A
Subjects:
Online Access: Get full text
Summary: Neurologic damage often leads to neuropathic pain, for which there are no effective treatments owing to its complex pathogenesis. The purinergic receptor P2X4 is closely associated with neuropathic pain. Astragalin (AST), a compound that is used in traditional Chinese medicine, has protective effects against allergic dermatitis and neuronal injury, but its mechanism of action is not well understood. The present study investigated whether AST can alleviate neuropathic pain in a rat model established by chronic constriction injury (CCI) to the sciatic nerve. The model rats exhibited pain behavior and showed increased expression of P2X4 and the activated satellite glial cell (SGC) marker glial fibrillary acidic protein in dorsal root ganglia (DRG). AST treatment partly abrogated the upregulation of P2X4, inhibited SGC activation, and alleviated pain behavior in CCI rats; it also suppressed ATP-activated currents in HEK293 cells overexpressing P2X4. These data demonstrate that AST relieves neuropathic pain by inhibiting P2X4 and SGC activation in DRG, highlighting its therapeutic potential for clinical pain management.
Bibliography: Edited by: Cesar Mattei, Université d’Angers, France
This article was submitted to Neuropharmacology, a section of the journal Frontiers in Neuroscience
Reviewed by: Li Zhang, National Institutes of Health (NIH), United States; Michael Morgan, The University of Melbourne, Australia
These authors share first authorship
ISSN: 1662-4548
1662-453X
1662-453X
DOI: 10.3389/fnins.2020.570831